RECRUITING

Compare Airway Pressure Release Ventilation (APRV) to Conventional Mechanical Ventila

Talk to us

Conditions

Gynecologic CancerGenitourinary Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a pilot study to determine if pulmonary function (lung compliance and ventilation/perfusion matching) is improved using APRV during general anesthesia, compared to the standard CMV. APRV will be tested during anesthesia in 12 patients undergoing robotic-assisted gynecological or genitourinary surgical procedures for definitive cancer treatment, who will also receive CMV.

Official Title

Pilot Study to Compare Airway Pressure Release Ventilation (APRV) to Conventional Mechanical Ventilation (CMV) During Anesthesia for Robotic-Assisted Gynecological and Genitourinary Operative Procedures

Quick Facts

Study Start:2025-08
Study Completion:2026-07
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07111039

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants must have histologically or cytologically confirmed gynecological or genitourinary cancer.
  2. * Subjects will have the physiologic reserve to undergo a robotic-assisted gynecological or genitourinary surgical procedure that uses anesthesia via Airway Pressure Release Ventilation and via Conventional Mechanical Ventilation.
  3. * Adults (≥18 years old)
  4. * ECOG performance status ≤ 2.
  5. * Ability to understand and the willingness to sign a written informed consent document.
  1. * Vulnerable subjects will not be enrolled for this study.
  2. * Patients who have COPD and are on oxygen at home or who have COPD requiring routine daily inhalers or daytime oxygen are excluded.
  3. * Patients who have history of major lung resection are excluded.
  4. * Patients with body mass index (BMI) \>50 are excluded.
  5. * Patients with pulmonary infection within the past 2 months of screening are excluded.
  6. * The availability of oxygen to a fetus during this experimental procedure has not been established. Therefore, patients known to be pregnant per operating room (OR) policy will be excluded.

Contacts and Locations

Study Contact

David Thrush, MD
CONTACT
813-745-2622
David.Thrush@moffitt.org

Principal Investigator

David Thrush, MD
PRINCIPAL_INVESTIGATOR
Moffitt Cancer Center

Study Locations (Sites)

Moffitt Cancer Center
Tampa, Florida, 33612
United States

Collaborators and Investigators

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

  • David Thrush, MD, PRINCIPAL_INVESTIGATOR, Moffitt Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-08
Study Completion Date2026-07

Study Record Updates

Study Start Date2025-08
Study Completion Date2026-07

Terms related to this study

Additional Relevant MeSH Terms

  • Gynecologic Cancer
  • Genitourinary Cancer